CAMELA, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 723
EU - Europa 316
AS - Asia 62
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.127
Nazione #
US - Stati Uniti d'America 715
IT - Italia 89
DE - Germania 82
IN - India 41
FR - Francia 33
NL - Olanda 33
CI - Costa d'Avorio 22
GB - Regno Unito 21
UA - Ucraina 15
FI - Finlandia 9
SE - Svezia 9
BG - Bulgaria 8
IE - Irlanda 8
CA - Canada 7
CN - Cina 7
HK - Hong Kong 3
JP - Giappone 3
KR - Corea 3
PL - Polonia 3
SG - Singapore 3
ES - Italia 2
AU - Australia 1
BE - Belgio 1
DZ - Algeria 1
EU - Europa 1
HU - Ungheria 1
ID - Indonesia 1
IL - Israele 1
LT - Lituania 1
MX - Messico 1
RO - Romania 1
ZA - Sudafrica 1
Totale 1.127
Città #
Chandler 150
Ashburn 137
Amsterdam 32
Lawrence 32
Napoli 31
Millbury 26
Boston 19
Wilmington 19
Washington 17
Des Moines 16
Naples 16
Menlo Park 15
Krefeld 12
Fairfield 11
Seattle 11
Houston 10
Pune 9
Woodbridge 9
Sofia 8
Milan 7
Bhubaneswar 5
Helsinki 5
Fremont 4
Kronberg 4
Lappeenranta 4
Redwood City 4
Esslingen am Neckar 3
Frankfurt am Main 3
Gangnam-gu 3
Hyderabad 3
Roccasecca 3
Rottweil 3
San Giuseppe Vesuviano 3
Segrate 3
Tokyo 3
Boardman 2
Council Bluffs 2
Dublin 2
Edinburgh 2
Milazzo 2
Paris 2
Paternò 2
Rietheim-Weilheim 2
San Diego 2
Studzianki 2
Véry 2
Algiers 1
Augusta 1
Battipaglia 1
Birmingham 1
Bordeaux 1
Borås 1
Boulder 1
Brussels 1
Bucharest 1
Budapest 1
Cambridge 1
Central 1
Cologne 1
Duncan 1
Elora 1
Ferrol 1
Folignano 1
Giugliano in Campania 1
Guangzhou 1
Gunzenhausen 1
Hangzhou 1
Hutchinson 1
Jakarta 1
Johannesburg 1
Las Palmas 1
Magenta 1
Melbourne 1
Montreal 1
Mountain View 1
Mussidan 1
New Orleans 1
New York 1
Norwalk 1
Ottawa 1
Quartu Sant'elena 1
San Nicolás de los Garza 1
Schoenwalde 1
Tel Aviv 1
Valle 1
Vancouver 1
Vilnius 1
Warsaw 1
Wuhan 1
Totale 705
Nome #
An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy- a new subtype? 81
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 73
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 60
Apremilast efficacy and safety in elderly psoriasis patients over a 48-weeks period 52
Generalized violaceous maculopapular rash and multiple verrucous nodules on the testes: a case of secondary syphilis misdiagnosed as lymphoma 44
A new dermoscopic pattern for chilblain-COVID-19–like skin lesions in adolescents 43
Erythrodermic Pityriasis Rubra Pilaris treatment: two case reports and literature review 36
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II 33
Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case 32
Anti‐interleukin‐23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice 31
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data 29
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge 29
Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period 28
New frontiers in personalized medicine in psoriasis 26
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 24
Hereditary Angioedema Type III, Recurrent Pregnancy Loss and Heterozygous MTHFR Mutation 24
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 24
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 24
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-centre retrospective study in a real-life setting 23
A case of erythrodermic psoriasis successfully treated with guselkumab 23
Ciprofloxacin-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) in a psoriasis patient 23
Nail changes as manifestation of systemic disease in COVID‐19 infection 23
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 23
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 22
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience 22
Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period 22
A case of pediatric psoriasis successfully and rapidly treated with ixekizumab 21
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 19
Reply to "Where are the older adults? Age distribution of nail psoriasis-randomized clinical trials' participants: a systematic review" by Ricardo JW et al 19
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review 19
A case of erythrodermic psoriasis successfully treated with apremilast 19
Reply to ‘New‐onset cutaneous lichen planus triggered by COVID‐19 vaccination’ by Merhy et al 19
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 18
Adalimumab biosimilar in a pediatric patient: clinical and in vivo reflectance confocal microscopy evaluation 17
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 17
Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis? 17
Teledermatology: a useful tool also after Covid-19 era? 17
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 17
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 15
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 14
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 14
Treating psoriasis in the elderly: biologics and small molecules 14
Towards Personalized Medicine in Psoriasis: Current Progress 10
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 9
Reply to "Routine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center retrospective cohort study" 9
Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series 8
A Case of Adult-onset Facial Cutaneous Mastocytoma: Clinical and Dermoscopic Findings 7
Topical oil formulation of plant extracts and vitamins as effective treatment for stretch marks and xerosis—An observational longitudinal study 7
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 6
Ixekizumab in scalp psoriasis: Clinical, dermoscopical, and in vivo reflectance confocal microscopy evaluation 6
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 6
Paradoxical reactions to biologicals for psoriasis 5
Giant basal cell carcinoma of the vulva successfully treated with Sonidegib 2
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 2
Totale 1.227
Categoria #
all - tutte 4.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.834


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 1 1 2 10 6
2020/2021151 2 4 2 1 7 10 2 45 62 8 8 0
2021/2022277 1 7 0 14 15 6 8 17 63 41 24 81
2022/2023454 37 35 15 17 39 56 49 64 65 36 32 9
2023/2024325 24 46 33 40 39 88 6 49 0 0 0 0
Totale 1.227